JAY W. MARKS, M.D.; SHU-PING LAN; RICHARD A. BAUM, M.D.; ROBERT L. HABIG, Ph.D.; RUSSELL F. HANSON, M.D.; THEODORE HERSH, M.D.; N.C. HIGHTOWER Jr, M.D.; ALAN F. HOFMANN, M.D.; JOHN M. LACHIN, Sc.D.; ELLIOTT C. LASSER, M.D.; HAGOP MEKHJIAN, M.D.; RONALD OKUN, M.D.; ROBERT A. SCHAEFER, M.D.; LESLIE J. SCHOENFIELD, M.D.; ROGER D. SOLOWAY, M.D.; JOHNSON L. THISTLE, M.D.; FRED B. THOMAS, M.D.; MALCOLM P. TYOR, M.D.
Chenodiol is a safe and effective agent for the medical dissolution of gallstones in selected patients; however, after dissolution and cessation of treatment, gallstones recur. This study was done to determine the recurrence rate after successful medical treatment and cessation of chenodiol therapy; compare the efficacy and safety of low-dose chenodiol, as compared to placebo, for prophylaxis against recurrence; and identify factors predictive of recurrence. In a randomized, double-blind fashion, 53 patients with gallstone dissolution received either chenodiol, 375 mg/d, or placebo, for at least 2 years. Standardized oral cholecystograms were done at 6 months, 1 year, and then yearly thereafter. Routine laboratory testing was done every 6 months. The cumulative rate of recurrence (life-table) was 27% in patients followed for up to 3.5 years. Chenodiol, 375 mg/d, was ineffective in preventing the recurrence of gallstones. No demographic, clinical, roentgenographic, or biochemical characteristics were predictive of recurrence.
JAY W. MARKS, SHU-PING LAN, RICHARD A. BAUM, ROBERT L. HABIG, RUSSELL F. HANSON, THEODORE HERSH, et al. Low-Dose Chenodiol to Prevent Gallstone Recurrence After Dissolution Therapy. Ann Intern Med. 1984;100:376–381. doi: 10.7326/0003-4819-100-3-376
Download citation file:
Published: Ann Intern Med. 1984;100(3):376-381.
Biliary Disorders, Gastroenterology/Hepatology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use